NCT06664125 Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
| NCT ID | NCT06664125 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Jemincare |
| Condition | Hyperphosphatemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2024-12-30 |
| Primary Completion | 2025-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 50 participants in total. It began in 2024-12-30 with a primary completion date of 2025-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
Eligibility Criteria
Inclusion Criteria: 1. Able to understand the procedures of this trial and provide written informed consent voluntarily; 2. Age ≥ 18 years, male or female; 3. On a stable hemodialysis regimen at a frequency of two or three times per week for at least 12 weeks prior to the screening visit; 4. Serum phosphorus within the trial-required range. Exclusion Criteria: 1. Any history of inflammatory bowel disease or diarrheal irritable bowel syndrome; 2. Pregnant or breastfeeding; 3. Any history of a parathyroid intervention; 4. Diarrhea or loose stools occurred within 1 week prior to randomization.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06664125 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hyperphosphatemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06664125 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06664125 currently recruiting?
Yes, NCT06664125 is actively recruiting participants. Contact the research team at xujing2@jemincare.com for enrollment information.
Where is the NCT06664125 trial being conducted?
This trial is being conducted at Guangzhou, China, Guangzhou, China.
Who is sponsoring the NCT06664125 clinical trial?
NCT06664125 is sponsored by Jemincare. The trial plans to enroll 50 participants.